Biosimilars in rheumatology: pharmacological and pharmacoeconomic issues.
作者： Giovanni Lapadula , Gian Franco Ferraccioli
DOI:
关键词: Medicine 、 Biosimilar Pharmaceuticals 、 Intensive care medicine 、 Psoriatic arthritis 、 Arthritis 、 Antirheumatic Agents 、 Health care 、 Disease 、 Biosimilar 、 Indirect costs 、 Physical therapy
摘要: … costs advantage compared with using the TNF inhibitor alone (11, 12). Results were similar in another pharmacoeconomic review of two cost-effectiveness and six cost-utility studies …
参考文章(12)
Islah Ahmed, Ben Kaspar, Uma Sharma, Biosimilars: Impact of Biologic Product Life Cycle and European Experience on the Regulatory Trajectory in the United States Clinical Therapeutics. ,vol. 34, pp. 400- 419 ,(2012) , 10.1016/J.CLINTHERA.2011.12.005
Melanie J Harrison, Challenges in assessing costs of rheumatoid arthritis. The Case Manager. ,vol. 14, pp. 65- 72 ,(2003) , 10.1016/S1061-9259(03)00208-X
T. Kirchhoff, J. Ruof, T. Mittendorf, M. Rihl, M. Bernateck, W. Mau, H. Zeidler, R. E. Schmidt, S. Merkesdal, Cost of illness in rheumatoid arthritis in Germany in 1997–98 and 2002: cost drivers and cost savings Rheumatology. ,vol. 50, pp. 756- 761 ,(2011) , 10.1093/RHEUMATOLOGY/KEQ398
A. Brennan, N. Bansback, R. Nixon, J. Madan, M. Harrison, K. Watson, D. Symmons, Modelling the cost effectiveness of TNF-α antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry Rheumatology. ,vol. 46, pp. 1345- 1354 ,(2007) , 10.1093/RHEUMATOLOGY/KEM115
Monika Schoels, John Wong, David L Scott, Angela Zink, Pamela Richards, Robert Landewé, Josef S Smolen, Daniel Aletaha, Economic aspects of treatment options in rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis Annals of the Rheumatic Diseases. ,vol. 69, pp. 995- 1003 ,(2010) , 10.1136/ARD.2009.126714
Akitoshi Tachihara, Makoto Tanno, Masakazu Nagashima, Atsuo Nakajima, Shinichi Yoshino, Ichiro Nakamura, Hisahiko Ohta, Katsumi Ito, Hidekazu Tanaka, Makoto Kobayashi, Modeling and cost-effectiveness analysis of etanercept in adults with rheumatoid arthritis in Japan: a preliminary analysis. Modern Rheumatology. ,vol. 16, pp. 77- 84 ,(2006) , 10.1007/S10165-006-0461-Y
E. M. Barrett, The impact of rheumatoid arthritis on employment status in the early years of disease: a UK community‐based study Rheumatology. ,vol. 39, pp. 1403- 1409 ,(2000) , 10.1093/RHEUMATOLOGY/39.12.1403
Quan V. Doan, Chiun-Fang Chiou, Robert W. Dubois, Review of Eight Pharmacoeconomic Studies of the Value of Biologic DMARDs Adalimumab, Etanercept, and Infliximab) in the Management of Rheumatoid Arthritis Journal of Managed Care Pharmacy. ,vol. 12, pp. 555- 569 ,(2006) , 10.18553/JMCP.2006.12.7.555
I. Filipovic, D. Walker, F. Forster, A. S. Curry, Quantifying the economic burden of productivity loss in rheumatoid arthritis Rheumatology. ,vol. 50, pp. 1083- 1090 ,(2011) , 10.1093/RHEUMATOLOGY/KEQ399
Y-F Chen, P Jobanputra, P Barton, S Jowett, S Bryan, W Clark, A Fry-Smith, A Burls, A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness. Health Technology Assessment. ,vol. 10, pp. 1- 266 ,(2006) , 10.3310/HTA10420